Lymphoma working group

Composition

Chair

Dr. M. Nijland (UCMG, Groningen) 

Vice-chair

Dr. S.H. Tonino  

Treasurer

pending

Secretary

Dr. A.E. Pulles (UMCU, Utrecht) 

Key objectives of working group

The key objectives of this working group are to:

• Initiate and implement (inter)national multicenter phase II and phase III clinical studies in the different subtypes of non-Hodgkin's lymphoma (NHL) and Hodgkin lymphoma (HL)
• Cooperate with international study groups, including the Nordic Lymphoma group, German HL study group, SAKK, EORTC, GELA and the European MCL network
• Collaborate with the HOP (HOVON pathology Group), to initiate and facilitate biological side studies linked to clinical studies.
• Collaborate with the HOVON imaging working group, to optimize imaging diagnostics with FDG-PET scans, CT scans and MRI (for the purpose of staging and response evaluation of lymphomas) and to initiate and facilitate secondary imaging studies).
• Collaborate with the HOVON Lunenberg Lymphoma Phase I/II Consortium (LLPC) to enable early access to promising new treatments for lymphoma patients
• Collaborate with the HOVON IEC working group, to develop studies and enable access to effector cell therapies
• Develop guidelines for diagnosis and treatment, and facilitate expert opinion
• Cooperate with Hematon, to optimize patient information and participation in studies
• Cooperate with IKNL, to support collecting population based data and research arising therefrom

Publication overview

• Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study
• A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients

Meetings & Minutes

Please note the section where meetings dates & minutes are shown are only accessible after log in.